

## **Europe Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029**

Market Report | 2024-02-17 | 80 pages | Mordor Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

### **Report description:**

The Europe Diabetes Drugs Market size is estimated at USD 16.43 billion in 2024, and is expected to reach USD 20.23 billion by 2029, growing at a CAGR of 4.25% during the forecast period (2024-2029).

The COVID-19 pandemic has substantially impacted the European Diabetes Drugs Market. People with diabetes have a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people. The manufacturers of diabetes drugs have taken care during COVID-19 to deliver the medications to diabetes patients with the help of local governments. NovoNordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.'

Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. According to the diabetes category, the estimated cost per hospital admission during the first wave of COVID-19 in Europe ranged from EUR 25,018 for type 2 diabetes patients in good glycemic control to EUR 57,244 for type 1 diabetes patients in poor glycemic control, reflecting a higher risk of intensive care, ventilator support, and a longer hospital stay. The estimated cost for patients without diabetes was EUR 16,993. The expected total direct expenditures for COVID-19 secondary care in Europe were 13.9 billion euros. Diabetes treatment thus accounted for 23.5% of total expenditures.

The European region had witnessed an alarming increase in the prevalence of diabetes, in recent years. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates by monitoring their blood glucose levels.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

#### Europe Diabetes Drugs Market Trends

The Oral anti-diabetic drugs segment held the highest market share in the Europe Diabetes Drugs Market in the current year

The Oral anti-diabetic drugs segment held the highest market share of 42.6% in the Europe Diabetes Drugs Market in the current year.

According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion and is expected to increase to USD 174 billion by 2040. These figures indicate that approximately 9% of the total healthcare expenditure is spent on diabetes in Europe. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs.

Oral Anti-Diabetic Drugs are available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. Anti-diabetic drugs help diabetes patients control their condition and lower the risk of diabetes complications. People with diabetes may need to take anti-diabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost. So they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.

The government and the companies are working towards better diabetes management. For instance, the National Service Framework (NSF) program is improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. Such advantages helped the rise in market growth.

Germany is Expected to Dominate the European Diabetes Drugs Market over the forecast period

Germany is expected to dominate the market and register a CAGR of about 3.9% over the forecast period.

Diabetes is a significant health problem and one of the extraordinary challenges for healthcare systems all over Germany. The prevalence of known type 1 & 2 diabetes in the German adult population is very high, along with many patients not yet diagnosed with the disease. Due to an aging population and unhealthy lifestyle, the prevalence of type 2 diabetes is expected to increase steadily over the next few years. High-quality care, including adequate monitoring, control of risk factors, and active self-management, are the key factors for preventing complications in German patients with type 2 diabetes.

The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients. Non-insulin treatments, used as first-line therapies for patients with type 2 diabetes, currently capture more than half the sales in the anti-diabetic market. Over the past decade, two important classes entered this market: dipeptidyl peptidase-4 inhibitors (DPP-4) and sodium-glucose cotransporter-2 inhibitors (SGLT-2). Oral anti-diabetic agents work in various ways to reduce blood sugar levels in people with type 2 diabetes. Some stimulate insulin secretion by the pancreas, and others improve the responsiveness of cells to insulin or prevent glucose production by the liver. Others slow the absorption of glucose after meals.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

According to the German Diabetes Centre (DDZ), about 8.5 million people in Germany are affected by diabetes. The number of people with type 2 diabetes in Germany will continue to increase over the next twenty years. German law requires public plans to cap out-of-pocket health care costs and to cover all medically necessary treatment, including insulin. Germany is one of the developed countries with advanced healthcare facilities. Moreover, reimbursement and pricing policies are highly regulated, which drives the market. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among people are some of the market opportunities for the players in the German market.

## Europe Diabetes Drugs Industry Overview

The European Diabetes Drugs Market is moderately fragmented with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, and other generic players. A major share of the market is held by manufacturers concomitant with strategy-based M&A operations and constantly entering the market to generate new revenue streams and boost existing ones. These measures taken by the market players will ensure a competitive marketplace, forcing companies to experiment with new technologies.

### Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

### **Table of Contents:**

#### 1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

#### 2 RESEARCH METHODOLOGY

#### 3 EXECUTIVE SUMMARY

#### 4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
- 4.4 Porter's Five Forces Analysis
  - 4.4.1 Bargaining Power of Suppliers
  - 4.4.2 Bargaining Power of Consumers
  - 4.4.3 Threat of New Entrants
  - 4.4.4 Threat of Substitute Products and Services
  - 4.4.5 Intensity of Competitive Rivalry

#### 5 MARKET SEGMENTATION

- 5.1 Insulins
  - 5.1.1 Basal or Long Acting Insulins
    - 5.1.1.1 Lantus (Insulin Glargine)
    - 5.1.1.2 Levemir (Insulin Detemir)
    - 5.1.1.3 Toujeo (Insulin Glargine)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.1.1.4 Tresiba (Insulin Degludec)
- 5.1.1.5 Basaglar (Insulin Glargine)
- 5.1.2 Bolus or Fast Acting Insulins
  - 5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
  - 5.1.2.2 Humalog (Insulin Lispro)
  - 5.1.2.3 Apidra (Insulin Glulisine)
- 5.1.3 Traditional Human Insulins
  - 5.1.3.1 Novolin/Actrapid/Insulatard
  - 5.1.3.2 Humulin
  - 5.1.3.3 Insuman
- 5.1.4 Biosimilar Insulins
  - 5.1.4.1 Insulin Glargine Biosimilars
  - 5.1.4.2 Human Insulin Biosimilars
- 5.2 Oral Anti-diabetic drugs
  - 5.2.1 Biguanides
    - 5.2.1.1 Metformin
  - 5.2.2 Alpha-Glucosidase Inhibitors
    - 5.2.2.1 Alpha-Glucosidase Inhibitors
  - 5.2.3 Dopamine D2 receptor agonist
    - 5.2.3.1 Bromocriptin
  - 5.2.4 SGLT-2 inhibitors □
    - 5.2.4.1 Invokana (Canagliflozin)
    - 5.2.4.2 Jardiance (Empagliflozin)
    - 5.2.4.3 Farxiga/Forxiga (Dapagliflozin)
    - 5.2.4.4 Suglat (Ipragliflozin)
  - 5.2.5 DPP-4 inhibitors
    - 5.2.5.1 Onglyza (Saxagliptin)
    - 5.2.5.2 Tradjenta (Linagliptin)
    - 5.2.5.3 Vipidia/Nesina (Alogliptin)
    - 5.2.5.4 Galvus (Vildagliptin)
  - 5.2.6 Sulfonylureas
    - 5.2.6.1 Sulfonylureas
  - 5.2.7 Meglitinides
    - 5.2.7.1 Meglitinides
- 5.3 Non-Insulin Injectable drugs
  - 5.3.1 GLP-1 receptor agonists □
    - 5.3.1.1 Victoza (Liraglutide)
    - 5.3.1.2 Byetta (Exenatide)
    - 5.3.1.3 Bydureon (Exenatide)
    - 5.3.1.4 Trulicity (Dulaglutide)
    - 5.3.1.5 Lyxumia (Lixisenatide)
  - 5.3.2 Amylin Analogue
    - 5.3.2.1 Symlin (Pramlintide)
- 5.4 Combination drugs
  - 5.4.1 Insulin combinations
    - 5.4.1.1 NovoMix (Biphasic Insulin Aspart)
    - 5.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.4.1.3 Kultophy (Insulin Degludec and Liraglutide)

5.4.2 Oral Combinations

5.4.2.1 Janumet (Sitagliptin and Metformin)

5.5 Geography

5.5.1 United Kingdom

5.5.2 Germany

5.5.3 Italy

5.5.4 Spain

5.5.5 France

5.5.6 Russia

5.5.7 Rest of Europe

6 MARKET INDICATORS

6.1 Type-1 Diabetic Population

6.2 Type-2 Diabetic Population

7 COMPETITIVE LANDSCAPE

7.1 COMPANY PROFILES

7.1.1 Takeda

7.1.2 Pfizer

7.1.3 Eli Lilly

7.1.4 Janssen Pharmaceuticals

7.1.5 Astellas

7.1.6 Boehringer Ingelheim

7.1.7 Merck And Co.

7.1.8 AstraZeneca

7.1.9 Bristol Myers Squibb

7.1.10 Novartis

7.1.11 Sanofi Aventis

7.1.12 Novo Nordisk A/S

7.2 COMPANY SHARE ANALYSIS

7.2.1 Novo Nordisk A/S

7.2.2 Sanofi Aventis

7.2.3 Eli Lilly

7.2.4 Merck And Co.

7.2.5 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Europe Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029**

Market Report | 2024-02-17 | 80 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

